With a diverse portfolio of industrial and commercial products, Ingersoll-Rand Plc (IR - Free Report) is a premier player in the industrial goods market. This Dublin, Ireland-based firm has a solid foundation of global brands with a leading market share in all major product lines.
After the divestiture of the commercial and residential security businesses, IR has been diligently focusing on improving the efficiencies and capabilities of its core businesses. The company is constantly on the lookout for opportunistic acquisitions to supplement its organic growth. However, IR operates in a competitive market place, which necessitates sustained investments in R&D initiatives to stay ahead of competition, thereby increasing its costs.
With rising operating costs and adverse currency translation effects shrinking margins, investors have been eagerly waiting for the company’s latest earnings report.
In the last four trailing quarters, IR has reported a positive average earnings surprise of 2.6%, beating earnings estimates twice. Currently, IR has a Zacks Rank #3 (Hold), but that could definitely change following first-quarter earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key stats from this just-revealed announcement below.
Earnings: IR beats on earnings. The Zacks Consensus Estimate called for EPS of 62 cents and the company reported adjusted continuing EPS of 70 cents.
Revenues: Revenues beat. IR posted revenues of $3,384.5 million, compared with the Zacks Consensus Estimate of $3,161 million.
Key Stats to Note: With diligent execution of operational plans and healthy end markets, IR delivered double-digit bookings and revenue growth in both segments. IR expects to exceed the high end of its prior guidance for 2018 and will offer an update of its guidance in concurrence with the second-quarter results.
Stock Price: Share prices did not show any movement in the pre-market trading following the release at the time of this write-up.
Check back for our full write up on this IR earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
With a diverse portfolio of industrial and commercial products, Ingersoll-Rand Plc (IR - Free Report) is a premier player in the industrial goods market. This Dublin, Ireland-based firm has a solid foundation of global brands with a leading market share in all major product lines.
After the divestiture of the commercial and residential security businesses, IR has been diligently focusing on improving the efficiencies and capabilities of its core businesses. The company is constantly on the lookout for opportunistic acquisitions to supplement its organic growth. However, IR operates in a competitive market place, which necessitates sustained investments in R&D initiatives to stay ahead of competition, thereby increasing its costs.
With rising operating costs and adverse currency translation effects shrinking margins, investors have been eagerly waiting for the company’s latest earnings report.
In the last four trailing quarters, IR has reported a positive average earnings surprise of 2.6%, beating earnings estimates twice. Currently, IR has a Zacks Rank #3 (Hold), but that could definitely change following first-quarter earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key stats from this just-revealed announcement below.
Earnings: IR beats on earnings. The Zacks Consensus Estimate called for EPS of 62 cents and the company reported adjusted continuing EPS of 70 cents.
Revenues: Revenues beat. IR posted revenues of $3,384.5 million, compared with the Zacks Consensus Estimate of $3,161 million.
Key Stats to Note: With diligent execution of operational plans and healthy end markets, IR delivered double-digit bookings and revenue growth in both segments. IR expects to exceed the high end of its prior guidance for 2018 and will offer an update of its guidance in concurrence with the second-quarter results.
Stock Price: Share prices did not show any movement in the pre-market trading following the release at the time of this write-up.
Check back for our full write up on this IR earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on IR - FREE